Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. 7 January 2020. Gaurav Singal.

Executive Summary

Over the past year, next-generation sequencing (NGS) company Foundation Medicine has ramped up publishing research on genetic markers for cancer in peer-reviewed journals. Gaurav Singal, Foundation Medicine's chief data officer, says he’s particularly proud of the company's portfolio of solid tissue and liquid biopsy assays that complement each other to help diagnose and treat cancers. Check out his comment here.

“At the end of the day, finding [a mutation] is great, but it's only important to the world if it impacts the patient's treatment decisions in a meaningful way.” – Gaurav Singal, chief data officer, Foundation Medicine Inc.

Click here for a free trial of Medtech Insight


Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts